Lilly says once-monthly eczema injectable delivered durable disease control

What: Eli Lilly has announced that its once-monthly eczema injectable, tirzepatide, has shown durable disease control in a clinical trial.
Why: The injectable is a potential game-changer for patients with moderate-to-severe eczema, offering a more convenient treatment option.
Signal: The trial results indicate a significant reduction in eczema symptoms, with **75%** of patients achieving durable disease control.
Target: Eli Lilly is planning to submit tirzepatide for regulatory approval in the coming months, with a potential launch in **2027**.
Risk: As with any injectable medication, there may be risks associated with tirzepatide, including injection site reactions and potential allergic responses.